Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα
Min Yan(Zhengzhou University), Hai‐long Piao(Dalian Institute of Chemical Physics), Guowang Xu(Dalian Institute of Chemical Physics), Huan Qi(Qingdao Institute of Bioenergy and Bioprocess Technology), Chang Lu(Shaanxi University of Chinese Medicine), Xiumei Liu(Dalian University of Foreign Languages), Xiaolong Liu(Tianjin University of Technology and Education), Wen Wang(Dalian Institute of Chemical Physics), Zhichao Wang(Jilin University), Zhen Ning(Dalian Medical University), Xinjie Zhao(Dalian Institute of Chemical Physics), Tian Xia(Dalian Institute of Chemical Physics), Di Chen(Chinese Academy of Sciences), Huan Chen(Zhejiang Chinese Medical University), Dinesh Singh Tekcham(Dalian Institute of Chemical Physics), Jing Liu(Chinese Academy of Sciences), Tongming Li(Dalian Institute of Chemical Physics)
Cited by 41
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway
|Oncotarget|2017|400
SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70
|Cellular and Molecular Immunology|2020|376